Patient recruitment at the speed of science

Learn how Sermonix Pharmaceuticals partnered with Tempus and its TIME network of clinical sites to accelerate patient recruitment for a phase 2 study.
Authors Sibel Blau, MD
President and CEO, Quality Cancer Care Alliance Network
Medical Director, Northwest Medical Specialties

Matthew Cooney, MD
Vice President, Therapeutic Development, Tempus

Read the full article here

Related Content

View more
  • post image

    Accelerate clinical trial enrollment and site activation

    Learn how TriHealth uses the TIME network to identify trial subjects and rapidly activate new clinical trials within its oncology portfolio within an average of ~10 business days.

    Watch replay
  • post image

    Tempus’ FDA approval and insights on the use of companion diagnostics in clinical development

    Tempus has recently announced the PMA approval for xT CDx, our solid tumor CDx and 648 gene panel.

    In this webinar, you will hear how the Tempus platform can support development of new therapies by combining real-world data, next-generation sequencing, and artificial-intelligence to advance precision oncology. Our regulatory and scientific experts will provide an overview of the pathways for diagnostics and share best practices for biopharma and biotech sponsors to consider in clinical trial design and the development of companion diagnostics.

    Watch replay
  • post image

    Using TIME to accelerate trial enrollment for Aadi Bioscience

    The Tempus TIME program provided Aadi access to a network of providers and patients to accelerate enrollment for its PRECISION 1 TSC1/TSC2 phase 2 clinical trial. Read on to learn how the TIME program decreased time to enroll with the just-in-time activation of ~10 business days.

    Read more